Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
Introduction:Androgen deprivation therapy is the first line of treatment for advanced prostate cancer (PC). However, PC progressed in most patients when it becomes resistant to castration. This study aimed to investigate the possible role of interleukin-23 (IL-23), a cytokine expressed in various ca...
Guardado en:
Autores principales: | Cihan Gündoğan, Nurhan Ergül, Huriye Serin, Ediz Beyhan, Burçak Yılmaz, Tevfik Fikret Çermik |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Galenos Yayinevi
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2afe482c1b2845f1b120ccbc4fe57550 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparison of <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer
por: Julien Van Damme, et al.
Publicado: (2021) -
68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors
por: Heying Duan, et al.
Publicado: (2022) -
Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Kristin A. Plichta, et al.
Publicado: (2021) -
Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
por: Paola Mapelli, et al.
Publicado: (2021) -
Design and synthesis of a new conjugate of a tris(3-hydroxy-4-pyridinone) chelator (KC18) for potential use as gallium-68-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical
por: Xu Zhou, et al.
Publicado: (2021)